

OFFICE OF FISCAL ANALYSIS

Legislative Office Building, Room 5200

Hartford, CT 06106 ◊ (860) 240-0200

<http://www.cga.ct.gov/ofa>

SB-197

AN ACT CONCERNING BIOLOGICAL PRODUCTS. AMENDMENT

LCO No.: 5020

File Copy No.: 96

Senate Calendar No.: 80

OFA Fiscal Note

See Fiscal Note Details

The amendment eliminates the potential savings reductions to the state and municipal health plans of the underlying bill by removing the prohibition on mail order for interchangeable biologics. The amendment makes changes to notice requirements which do not change the fiscal impact of the underlying bill. Lastly, the amendment makes other changes regarding the delivery of biologics which do not result in a fiscal impact.

The preceding Fiscal Impact statement is prepared for the benefit of the members of the General Assembly, solely for the purposes of information, summarization and explanation and does not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

Primary Analyst: HW
Contributing Analyst(s):

5/3/18
(FN)